Key Metrics of Azitra Inc
Revenue$686K▲ 141.5% YoYFY 2023
Operating income−$7.5M▲ 21.2% YoY
Net profit−$11.3M▼ 5.6% YoY
Shareholders' equity$2.9M
Market cap$5.5MAZTR · $0.90
Competitors10identified
About Azitra Inc
Sectors
Company details
- Founded
- 2023
- Listed
- NYSE: AZTR (since 2023)
Operational Areas of Azitra Inc
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameAzitra Inc
TickerAZTR
ExchangeNYSE
CountryUnited States
SEC CIK0001701478
Listed since2023
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
AZTR · NYSE · SEC CIK 0001701478
Last price · 30 Oct 2026
$0.90
−19.23%
Market cap$5.5M
P/E—On FY 2023 diluted EPS
Volume2,687,723
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPO—Listed 2023
AZTR share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Azitra Inc
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | 10xgenomics.com | 2019 | United States |
Similar companies
A
Alector Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
P
Palisade Bio Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
E
Entera Bio Ltd.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
W
Wave Life Sciences Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
A
Ardelyx Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
CeriBell Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
N
Nuvation Bio Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
S
Septerna Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.